FIELD: medicine.
SUBSTANCE: what is offered is a modified botulinum toxin containing a natural heavy chain and a modified light chain. What is described is using the modified botulinum toxin for preparing a drug for treating dystonia, and also for eliminating face wrinkles. Nucleic acid coding the modified botulinum toxin is presented. Also, a vector containing nucleic acid, and a host cell containing the vector are also presented.
EFFECT: higher stability and prolonged therapeutic action.
22 cl, 2 dwg, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
| NEUROTOXINS SHOWING SHORTENED BIOLOGICAL ACTIVITY | 2012 |
|
RU2646110C2 |
| SORTASE-LABELED CLOSTRIDIA NEUROTOXINS | 2020 |
|
RU2801120C2 |
| SUPPRESSION OF ALLODYNIA INDUCED BY BONE CANCER | 2019 |
|
RU2791640C2 |
| THERAPEUTIC FUSION PROTEINS | 2012 |
|
RU2651492C2 |
| CATIONIC NEUROTOXINS | 2015 |
|
RU2733493C2 |
| FVIII MODIFICATION TREND SITE | 2005 |
|
RU2423380C2 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| METHOD OF PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDE | 2012 |
|
RU2673910C2 |
